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Abstract: Obesity constitutes a critical risk factor for the development of many life threatening 
diseases, particularly insulin resistance and type 2 diabetes. Adipose tissue plays an important 
role in regulating whole body energy homeostatsis and obesity-related insulin resistance. 
Inﬂ  ammation has been commonly linked to insulin resistance. Recent studies demonstrated that 
adipose tissue is an important source for producing inﬂ  ammatory molecules in the obese state, 
primarily due to accumulation of macrophages. Animal models deﬁ  cient in key inﬂ  ammatory 
molecules or with reduced adipose macrophage inﬁ  ltration are protected from development of 
obesity-related insulin resistance. Repression of adipose inﬂ  ammation may be a useful approach 
to ameliorate obesity-associated metabolic disorders.
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Correlation between obesity-related insulin 
resistance and inﬂ  ammation
Approximately 30% of US adults and 20% of school-aged children are obese. Obesity 
has become an epidemic disease and its incidence is still rapidly increasing at an alarm-
ing rate (Hill et al 2003). The hallmark of obesity is manifested by massive expansion 
of adipose tissue, attributable to excessive food consumption and sedentary life style in 
modern society. Obesity has been identiﬁ  ed as a major risk factor for the development 
of many life-threatening diseases, such as hypertension, atherosclerosis, dyslipidemia, 
and particularly type 2 diabetes (Kopelman 2000). Type 2 diabetes itself is also a risk 
factor for the development of heart disease and stroke. As a matter of fact, more than 
65% of people with diabetes die from heart disease or stroke. The underlying molecular 
mechanism for obesity-related metabolic disorders is still not well understood. The 
correlation between obesity, diabetes and inﬂ  ammation have been observed as early 
as several decades ago, when increased circulating levels of acute phase proteins, such 
as ﬁ  brinogen, haptoglobin, and α-1 antitripsin, were reported (Fearnley et al 1959; 
Ogston and McAndrew 1964; Ganrot et al 1967). In more recent studies, elevated serum 
concentrations of more acute phase proteins were shown, including sialic acid, α-1 
acid glycoprotein, C-reactive protein (CRP) and serum amyloid A (Crook et al 1993; 
Pickup et al 1997). In addition, inﬂ  ammatory proteins such as IL-6 and plasminogen 
activator inhibitor 1 (PAI-1), as well as increased white cell count are also found to 
correlate with type 2 diabetes (Festa et al 2002; Pradhan et al 2001; Vozarova et al 
2002). However, ﬁ  ndings from these human population studies alone were not sufﬁ  cient 
to stimulate thoughts regarding whether inﬂ  ammation could be a causative factor for 
the pathogenesis of obesity-related insulin resistance and type 2 diabetes.
Recent studies indicate that inﬂ  ammatory event in the adipose tissue may play 
a critical role in the development of insulin resistance. Tumor necrosis factor-α 
(TNFα) is the ﬁ  rst cytokine identiﬁ  ed with elevated expression in adipose tissue from 
obese rodents and humans, resulting from both increased production and abnormal Diabetes, Metabolic Syndrome and Obesity 2008:1 26
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processing (Hotamisligil et al 1993, 1995; Xu et al 2002b). 
TNFα inhibits signaling from the insulin receptor and 
neutralization of TNFα by infusion with a tumor necrosis 
factor receptor-immunoglobin G (TNFR-IgG) chimeric 
protein improves insulin sensitivity (Feinstein et al 1993; 
Hotamisligil et al 1993, 1994). TNFα can also cause dys-
regulated lipolysis in adipocytes, therefore potentially con-
tributes to the elevation of circulating free fatty acid (FFA) 
concentration (Green et al 1994). FFA has been demonstrated 
to be a critical factor for causing systemic insulin resistance 
in multiple tissues, such as liver and muscle. The discovery 
that inﬂ  ammatory cytokine TNFα impairs insulin signaling 
greatly stimulated the ﬁ  eld and scientists started to view 
that inﬂ  ammation may be a causative event for the patho-
genesis of obesity-related insulin resistance. Subsequently, 
more cytokines, chemokines and other secretary proteins 
are found to increase in adipose tissue of obese rodents 
and/or humans, including leptin, interleukin-6 (IL-6), 
IL-8, monocyte chemotactic factor 1 (MCP-1), angioten-
sinogen, visfatin, resistin, retinol-binding protein-4, serum 
amyloid A (SAA). Among these molecules, IL-6, IL-8, and 
MCP-1 have been reported to impair insulin action (Rotter 
et al 2003; Sartipy and Loskutoff 2003). The reason that 
cytokine and chemokine production increases in response to 
triglyceride accumulation in adipose tissue is not clear. One 
possibility is that these factors might have designated roles 
to limit excessive fat mass expansion, which unfortunately 
is at the cost of inducing insulin resistance. Consistent with 
this hypothesis, TNFα, IL-8, and MCP-1 have been reported 
to inhibit adipocyte differentiation (Xu et al 1999; Gerhardt 
et al 2001; Xu and Hotamisligil 2001). Animals deﬁ  cient in 
CCR2, the major receptor of MCP-1, have larger adipocytes 
but are more insulin sensitive (Weisberg et al 2006). This 
hypothesis is further supported by two animal models: adi-
pose tissue TNFα transgenic and fat-speciﬁ  c insulin receptor 
knockout mice. Both models demonstrated reduced adiposity 
but accompanied by severely impaired insulin signaling in 
adipose tissue (Bluher et al 2002; Xu et al 2002a). However, 
the systemic insulin sensitivity has been improved despite 
adipose insulin resistance, suggesting the importance of 
overall fat mass on metabolism.
Animal models deﬁ  cient 
in key inﬂ  ammatory molecules
Intensive investigations with various animal models deﬁ  cient 
in key molecules in the inﬂ  ammatory pathway further pro-
vided solid evidence for the causative role of inﬂ  ammation 
in the development of obesity-related insulin resistance. 
The ﬁ  rst proof of principle animal model is TNFα-deﬁ  cient 
mice. In the absence of TNFα, mice are partially protected 
from development of hyperlipidymia, hyperglycemia and 
hyperinsulinemia without an effect on body weight in obe-
sity models induced by high fat diet, deﬁ  ciency of leptin, or 
gold-thioglucose injection (Uysal et al 1997; Ventre et al 
1997). Increased tyrosine phosphorylation of insulin recep-
tor was observed in both adipose tissue and muscle in obese 
mice deﬁ  cient in TNFα. In addition, KB-R7785, a synthetic 
compound that inhibits TNFα production, can improve 
insulin sensitivity in obese/diabetic KKAy mice (Morimoto 
et al 1997). These in vivo data support a role of TNFα as 
a candidate mediator of obesity-induced insulin resistance 
but also indicate the involvement of other factors since the 
protection is partial. TNFα signals through two receptors, 
p55 and p75. The role of TNFα receptors in mediating 
the effect of TNFα on obesity-related insulin resistance is 
controversial in two independent studies, which might be 
attributable to differences in genetic backgrounds (Schreyer 
et al 1998; Uysal et al 1998).
Recently, the c-Jun NH2-terminal kinase (JNK) has 
appeared as a vital regulator in obesity and insulin resis-
tance. Both TNFα and FFA are potent stimulators for JNK 
activation. Indeed, JNK activity is elevated in liver, adipose 
tissue and muscle in both diet-induced obese mice and 
ob/ob mice (Hirosumi et al 2002). Interestingly, different 
JNK isoforms seem to play distinct roles. JNK1 deﬁ  cient 
mice have decreased adiposity and adipocyte size, increased 
serum adiponection and lowered serum resistin concentra-
tions, lowered glucose and insulin concentrations, enhanced 
insulin signaling in the liver and improved whole body insulin 
sensitivity upon high fat diet (Hirosumi et al 2002). Absence 
of JNK1 also partially protected ob/ob mice from developing 
hyperglycemia and hyperinsulinemia (Hirosumi et al 2002). 
In contrast, deﬁ  ciency of JNK2 does not have any inﬂ  uence 
on diet-induced insulin resistance. These results demonstrate 
that JNK1 accounts for the majority of increased JNK activ-
ity in insulin target tissues and is an important regulator in 
obesity-related insulin resistance.
IKKβ, the master regulator of inﬂ  ammation which can 
also be activated by TNFα and FFA, is another important 
serine kinase involved in the development of obesity-related 
insulin resistance. Homozygous IKKβ deﬁ  ciency is lethal due 
to increased liver apoptosis but heterozygous IKKβ+/− mice 
appear normal. Lowered fasting glucose and insulin concen-
trations were observed in IKKβ+/− mice on both standard diet 
and high-fat diet compared to wild-type littermates (Yuan et al 
2001). Furthermore, absence of one IKKβ allele is sufﬁ  cient Diabetes, Metabolic Syndrome and Obesity 2008:1 27
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to lower blood glucose and plasma FFA levels as well as 
improve glucose tolerance in ob/ob mice (Yuan et al 2001). 
Arkan and colleagues (2005) further selectively deleted IKKβ 
in hepatocytes or myeloid cells and showed that IKKβ deﬁ  -
ciency in hepatocytes locally protected liver from develop-
ment of obesity-related insulin resistance, but fat and muscle 
still develop insulin resistance upon high fat diet. Consistent 
with these results, transgenic mice selectively expressing the 
constitutively active form of IKKβ in the liver have increased 
hepatic production of proinﬂ  ammatory cytokines, which 
caused profound hepatic insulin resistance (Cai et al 2005). 
In addition, these proinﬂ  ammatory cytokines also cross talk 
with other tissues and lead to hyperglycemia, and modest 
systemic insulin resistance (Cai et al 2005). Interestingly, spe-
ciﬁ  c deletion of IKKβ in myeloid cells of diet-induced obese 
mice or ob/ob mice is sufﬁ  cient to improve systemic insulin 
sensitivity, which is attributable to decreased production of 
proinﬂ  ammatory cytokines or chemokines that are known to 
inhibit insulin signaling in cultured cells (Arkan et al 2005). 
These data demonstrate that IKKβ plays an important role in 
the development of obesity-related insulin resistance by acting 
in multiple cell types, particularly myeloid cells.
TLR4, a family member of toll-like receptors (TLRs), 
plays a critical role in pattern recognition and activation of 
innate immunity (Medzhitov et al 1997). Lipopolysaccharide 
(LPS) is the well characterized ligand for TLR4 (Poltorak 
et al 1998). Several recent studies demonstrate that FFAs, 
whose levels are elevated in obesity, can also activate 
TLR4 (Lee et al 2001). Deﬁ  ciency of TLR4 can prevent 
FFA-induced production of inﬂ  ammatory cytokines in both 
macrophages and adipocytes. In lipid-infused animals, 
absence of TLR4 signiﬁ  cantly improved insulin signaling in 
muscle and decreased production of inﬂ  ammatory cytokines 
in adipose tissue (Shi et al 2006). Absence of TLR4 also mod-
estly improved systemic insulin sensitivity in female mice 
upon high fat challenge, presumably through reduced produc-
tion of proinﬂ  ammatory cytokines in liver and adipose tissue. 
Similar phenotypes are also observed in diet-induced obese 
mice with a loss-of-function mutation in TLR4, conﬁ  rming 
a role of TLR4 in linking innate immunity and lipid-induced 
insulin resistance (Tsukumo et al 2007).
Adipose tissue macrophage 
accumulation in obesity
Despite the substantive amount of data demonstrating the link 
between inﬂ  ammation and obesity-related insulin resistance, 
the speciﬁ  c cell source for production of inﬂ  ammatory mol-
ecules are unclear though it appears to be originated from 
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Figure 1 Mechanism of adipose macrophage inﬁ  ltration and the role of adipose inﬂ  ammation in systemic insulin resistance.   Accumulation of triglycerides in adipocytes 
causes increased production of MCP-1 and the other monocyte chemotactic factors, which attract circulating monocytes to migrate into adipose tissue.   These inﬂ  amed 
monocytes mature into classically activated macrophages and secrete a variety of proinﬂ  ammatory factors that can impair insulin signaling in adipocytes. Dysregulated adipocyte 
lipolysis contributes to elevation of circulating FFA level which subsequently induces insulin resistance in other tissues such as liver and muscle.Diabetes, Metabolic Syndrome and Obesity 2008:1 28
Jiao and Xu
adipose tissue. It was originally thought that adipocytes are 
the cell type that produces proinﬂ  ammatory factors. It has 
been shown that adipocytes possess many features of immune 
cells and adipocyte precursors have phagocytic capacity and 
can be converted into macrophage-like cells in response to 
certain stimuli (Cousin et al 1999; Charriere et al 2003). 
Two studies in 2003, which used transcription proﬁ  ling 
approach to compare adipose tissue from lean and several 
rodent obesity models, or adipose tissue from obese animals 
before and after treatment with compounds of the thiazoli-
dinedione class of anti-diabetic agents, have showed that the 
majority of genes signiﬁ  cantly upregulated in obese adipose 
tissue are macrophage and inﬂ  ammatory genes, which can 
be repressed by rosiglitazone (Weisberg et al 2003; Xu et al 
2003). By separating adipocytes from stromal-vascular cells 
and histological examination, these studies revealed massive 
macrophage accumulation in adipose tissue in the obese state. 
Bone marrow transplant study further demonstrated that these 
macrophages are predominantly inﬁ  ltrated, rather than con-
verted from local preadipocytes. Activated macrophages are 
known to secrete a variety of pro-inﬂ  ammatory cytokines and 
chemokines. In these two studies, isolated stromal-vascular 
cells, the fraction containing inﬁ  ltrated macrophages, are 
demonstrated to be the predominant source for producing 
proinﬂ  ammatory molecules in comparison to adipocytes, 
including TNFα, MCP-1, IKKβ, IL-1β, and inducible nitric 
oxide synthase (iNOS). These results suggest that inﬁ  ltrated 
macrophages in adipose tissue in state of obesity are likely 
an important source contributing to elevation of circulating 
inﬂ  ammatory marker proteins. Blood mononuclear cells 
(MNCs) in the obese state are also reported to be in a pro-
inﬂ  ammatory state, as reﬂ  ected by increased nuclear factor 
kappa-B (NF-κB) binding activity, decreased IκB content and 
increased transcription of NF-κB controlled proinﬂ  ammatory 
genes, indicating that inﬂ  amed circulating MNCs may also 
contribute to elevation of circulating inﬂ  ammatory marker 
proteins as well (Ghanim et al 2004).
The triggering factors for macrophage inﬁ  ltration into 
adipose tissue and the roles of inﬁ  ltrating macrophages are 
still not well understood. One speculation is that enlarge-
ment of fat cells, which commonly occurs in obese state 
at relatively early stage, may trigger the initial secretion of 
critical monocyte chemotactic factors. Once macrophages 
inﬁ  ltrate into adipose tissue and get activated, they become 
the major source of inﬂ  ammatory molecules and continue 
to attract more macrophages to further amplify the harmful 
cycle. The prototype monocyte chemotactic factor, MCP-1, 
has been under intensive investigation as such a candidate 
for recruiting macrophages into adipose tissue in obesity 
since its expression is upregulated in adipose tissue in early 
stage of diet-induced obesity. However, controversial results 
have been reported for the role of MCP-1. One publication 
showed that mice deﬁ  cient in MCP-1 have partially reduced 
adipose tissue macrophage accumulation upon high fat diet 
and are accompanied with improved insulin sensitivity and 
hepatic steatosis (Kanda et al 2006). Acute expression of a 
dominant-negative MCP-1 mutant also ameliorated insulin 
resistance in both diet-induced obese mice and db/db mice 
(Kanda et al 2006). Another publication demonstrated no 
change of adipose macrophage content in MCP-1 knock 
out mice (Inouye et al 2007). These results suggest the 
roles of other monocyte chemotactic factors. Nevertheless, 
reports from two independent laboratories reported that mice 
overexpressing MCP-1 transgene in adipose tissue under 
the promoter of adipocyte fatty acid binding protein have 
increased macrophage accumulation in adipose tissue and 
are insulin resistant (Kamei et al 2006; Kanda et al 2006). 
The major receptor of MCP-1 is CCR2, which also medi-
ates signaling of other monocyte chemotactic factors such 
as MCP-2 and MCP-3. Macrophages recruited into adipose 
tissue in obese state have increased expression of CCR2. 
Mice deﬁ  cient in CCR2 have a lean phenotype when fed on 
a high fat diet due to reduced food intake. When high fat-diet 
fed CCR2 deﬁ  cient mice and control mice are matched for 
adiposity, partially decreased adipose macrophage content 
was observed. These mice have improved inﬂ  ammatory pro-
ﬁ  le in adipose tissue, along with improved systemic insulin 
sensitivity and ameliorated hepatic steatosis (Weisberg et al 
2006). DIO mice treated with CCR2 antagonist have a 28% 
reduction of adipose macrophage content and have improved 
hyperglycemia (Weisberg et al 2006). These data suggest that 
CCR2 plays a role in adipose tissue macrophage recruitment 
in obese state and also point out the potential role(s) of other 
chemokine receptor(s) since absence of CCR2 only partially 
blocked macrophage inﬁ  ltration upon high fat diet.
Macrophages are phagocytic cells that clear pathogens, 
dead cells and cell debris in innate immunity and wound 
healing. It has been shown that adipocyte death increases 
signiﬁ  cantly in obese humans and mice via the mechanism of 
necrosis. The majority of inﬁ  ltrated macrophages in adipose 
tissue are localized around dead adipocytes to form crown-
like structure (CLS) (Cinti et al 2005). This scenario highly 
resembles atherosclerosis, which is caused by macrophage 
inﬁ  ltration into aorta to clean excessive cholesterol and 
subsequent formation of foam cells. Interestingly, frequency 
of adipocyte death in epidydimal fat pat correlates with Diabetes, Metabolic Syndrome and Obesity 2008:1 29
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the extent of macrophage inﬁ  ltration (Strissel et al 2007). 
These data indicate that inﬁ  ltrated macrophages are involved 
in clearance of cell debris, leaked lipids and perhaps are 
important for adipose tissue remodeling. Macrophages are 
heterogeneous in function and their properties and activation 
state are dependent upon local environment factors. Two 
polarization states, M1 or “classically activated” and M2 or 
“alternatively activated”, have been deﬁ  ned for macrophage 
activation. M1 macrophages have high proinﬂ  ammatory 
cytokine expression and produce reactive oxygen species; 
M2 macrophages express high levels of anti-inﬂ  ammatory 
cytokines, such as IL-10. IL-10 can selectively inhibit tran-
scription rates of inﬂ  ammatory gene and activate STAT3 to 
attenuate inﬂ  ammatory signals induced by TNFα. Macro-
phages inﬁ  ltrated into adipose tissue in obese state possess 
features of M1 macrophages and more importantly, macro-
phages in CLS express protein of TNFα and IL-6 (Lumeng 
et al 2007; Strissel et al 2007). In contrast, resident macro-
phages in adipose tissue of lean mice have many features of 
M2 macrophages, including expression of M2 macrophage 
characteristic genes such as Ym1, arginase 1, and IL-10. 
High fat diet is sufﬁ  cient to promote macrophage phenotypic 
switch from anti-inﬂ  ammatory M2 polarization to proinﬂ  am-
matory M1 polarization. Peroxisome proliferator activated 
receptor-γ (PPARγ), the molecular target for the anti-diabetic 
thiazolidinedione class of compounds, has been reported 
to play a key role in maturation of alternatively activated 
macrophages with anti-inﬂ  ammatory properties (Bouhlel 
et al 2007). Mice deﬁ  cient of PPARγ in myeloid cells have 
impaired activation of M2 macrophages, as demonstrated 
by decreased expression and activity of arginase, hallmarks 
of alternatively activated macrophages (Hevener et al 2007; 
Odegaard et al 2007). These mice have lower content of alter-
natively activated macrophages, increased local inﬂ  ammation 
in adipose tissue, impaired insulin signaling in adipose tissue, 
muscle, and liver on chow diet. These mice are also prone to 
the development of obesity-related insulin resistance. These 
results indicate that phenotypic switch from M2 to M1 mac-
rophages are critical for impairing insulin sensitivity.
Transient neutrophil inﬁ  ltration into adipose tissue in 
obesity is also reported, which occurs 3 and 7 days upon 
high fat diet in epididymal but not subcutaneous fat and 
disappears on all subsequent times points (Elgazar-Carmon 
et al 2008). A potential chemotactic factor for neutrophil 
inﬁ  ltration has been proposed to be IL-8, which can be 
secreted by adipose tissue in obesity. Neutrophils have 
been demonstrated to directly adhere to adipocytes and this 
process can be inﬂ  uenced by cations and activation state of 
neutrophils. The time course of adipose tissue neutrophil 
inﬁ  ltration precedes macrophage inﬁ  ltration, which does not 
start increase till 8 weeks upon high fat diet (Strissel et al 
2007). Neutrophil inﬁ  ltration reﬂ  ects acute inﬂ  ammation 
while macrophage inﬁ  ltration symbols chronic inﬂ  ammation. 
Activated neutrophils can release ROS and TNFα, whether 
inﬁ  ltrated neutrophils contribute to adipose inﬂ  ammation 
remains a question to be studied.
Targeting inﬂ  ammation 
as a potential therapeutic approach 
for improving insulin sensitivity
The ﬁ  ndings for a potential role of adipose inﬂ  ammation in 
the development of insulin resistance from animal models 
can also be extended to humans. Macrophage accumulation 
has been observed in human adipose tissue and the extent 
has strong positive correlation with BMI and adipocyte 
area but negatively related to insulin sensitivity (Weisberg 
et al 2003). The macrophage content is depot dependent. 
Omental fat of obese humans contains more macrophages 
than subcutaneous fat. Omental fat macrophage inﬁ  ltration 
correlates to fasting glucose, insulin and hepatic ﬁ  broinﬂ  am-
matory lesions in obese patients (Cancello et al 2006). In 
addition, obese subjects with impaired glucose homeostasis 
have preferential omental adipose macrophage inﬁ  ltration 
(Harman-Boehm et al 2007). Weight loss in obese subjects 
either through low calorie diet or bariatric surgery have 
decreased expression of inﬂ  ammatory factors and increased 
expression of anti-inﬂ  ammatory molecules, accompanied 
with decreased macrophage number and improved metabolic 
proﬁ  le (Clement et al 2004; Cancello et al 2005). These 
data suggest that anti-inﬂ  ammatory reagents or blockage of 
macrophage inﬁ  ltration into adipose tissue may be beneﬁ  cial 
for improving systemic insulin resistance in obese patients.
Inﬂ  ammation has been generally correlated with insulin 
resistance in many situations, such as trauma, burn and 
infection. Although it is a relatively recent ﬁ  nding that adi-
pose inﬂ  ammation is associated with obesity-related insulin 
resistance, the effect of anti-inﬂ  ammation reagent sodium 
salicylate on improving symptoms of diabetes mellitus was 
demonstrated a century ago (Williamson 1901). Later on, 
high dose aspirin was discovered to not only improve arthritis 
in a diabetic patient, but also make daily insulin injection 
unnecessary for controlling blood glucose level (Reid et al 
1957). Cessation of aspirin upon disappearance of joint 
symptoms caused recurrence of glucose intolerance. Sub-
sequent clinical trial with high dose-aspirin reconﬁ  rmed the Diabetes, Metabolic Syndrome and Obesity 2008:1 30
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effect on lowering blood glucose levels (Hecht and Goldner 
1959). The molecular target mediating the hypoglycemic 
effect of salicylates has now been identiﬁ  ed, which is IKKβ 
(Yuan et al 2001). IKKβ activates NF-κB, which is a master 
transcription factor that activates transcription of numerous 
inﬂ  ammatory genes. Potent small molecule inhibitor aginst 
IKKβ may be beneﬁ  cial for improving insulin reistance in 
obese subjects.
Another line of evidence that repression of inflam-
mation may be useful for controlling hyperglycemia in 
type 2 diabetic patients derives from the anti-inﬂ  ammatory 
effect of the widely used insulin sensitizer. Thiazolidin-
ediones (including rosiglitazone and pioglitazone), a new 
and highly efﬁ  cacious class of insulin-sensitizing drugs that 
mainly targeting adipose tissue by activating PPARγ, have 
been reported to have anti-inﬂ  ammatory effect. PPARγ is a 
ligand-dependent nuclear hormone receptor predominantly 
expressed in adipocyte and is a master regulator of adipo-
cyte differentiation. Expression of PPARγ is signiﬁ  cantly 
increased upon macrophage activation and treatment with 
thiazolidinediones inhibits production of monocyte inﬂ  am-
matory cytokines and expression of iNOS, gelatinase B and 
scavenger genes, partly through repressing the activities of 
transcription factors AP-1, STAT, and NF-κB. In animal 
models, PPARγ agonists have been reported to improve 
development of atherosclerosis (Li et al 2000; Stojanovska 
et al 2007). These results indicate that thiazolidinediones can 
repress macrophage-mediated inﬂ  ammation. Interestingly, 
atherosclerosis-prone apolipoprotein E-deﬁ  cient mice trans-
planted with inﬂ  amed visceral fat developed signiﬁ  cantly 
more atherosclerosis compared to sham-operated animals. 
Treatment with pioglitazone decreased macrophage content 
of the transplanted visceral fat tissue, reduced plasma MCP-1 
and reduced atherosclerosis (Ohman et al 2008). Ten-week 
treatment with pioglitazone in subjects with impaired glucose 
tolerance reduced macrophage number in adipose tissue and 
decreased inﬂ  ammatory cytokine production (Di Gregorio 
et al 2005). Furthermore, thiazolidinediones are also reported 
to suppress NF-κB activity in inﬂ  amed circulating MNCs 
in obese subjects (Ghanim et al 2001, 2006; Mohanty et al 
2004). These results suggest that the insulin sensitizing effect 
of thiazolidinediones could be partially achieved through 
repression of adipose tissue macrophage content and subse-
quent reduction of inﬂ  ammatory factor production.
In summary, substantive evidence derived from both 
animal models and human studies supports an important 
role of adipose inﬂ  ammation in the development of obesity-
related insulin resistance. Development of new therapeutic 
agents targeting improving adipose inﬂ  ammation, such as 
blocking macrophage inﬁ  ltration and preventing phenotypic 
switch of M2 to M1 macrophages, may be effective for 
attenuating insulin resistance and hyperglycemia associated 
with obesity.
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